Current Rheumatology Reports

, Volume 11, Issue 1, pp 36–40

Aspirin and acetaminophen: Should they be available over the counter?



Traditional nonsteroidal anti-inflammatory drugs block cyclooxygenase (COX). They are the most widely used drugs for pain relief. They are indispensable for their effects but are condemned for their adverse drug reactions. Two COX inhibitors, acetaminophen and aspirin, are the most widely used over-the-counter drugs. They have low (but useful) therapeutic activity, but they are endowed with specific risks that are not seen with most other COX inhibitors. Both are lethal if taken in overdose. Each is stigmatized by severe adverse effects. Aspirin results in prolonged inhibition of blood coagulation, and acetaminophen can result in liver toxicity at normal dose and liver failure at higher dose. Both drugs cause many deaths every year. We recommend that the status of both drugs be changed to prescription only. Their continued availability over the counter poses an unacceptable risk to the general population.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Lipsky PE, Abramson SB, Breedveld FC, et al.: Analysis of the effect of COX-2 specific inhibitors and recommendations for their use in clinical practice. J Rheumatol 2000, 27:1338–1340.PubMedGoogle Scholar
  2. 2.
    Strand V: Are COX-2 inhibitors preferable to non-selective non-steroidal anti-inflammatory drugs in patients with risk of cardiovascular events taking low-dose aspirin? Lancet 2007, 370:2138–2151.PubMedCrossRefGoogle Scholar
  3. 3.
    Hinz B, Brune K: Can drug removals involving cyclooxygenase-2 inhibitors be avoided? A plea for human pharmacology. Trends Pharmacol Sci 2008, 29:391–397.PubMedCrossRefGoogle Scholar
  4. 4.
    Kearney PM, Baigent C, Godwin J, et al.: Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 2006, 332:1302–1308.PubMedCrossRefGoogle Scholar
  5. 5.
    Bresalier RS, Sandler RS, Quan H, et al.: Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005, 352:1092–1102.PubMedCrossRefGoogle Scholar
  6. 6.
    Solomon SD, McMurray JJ, Pfeffer MA, et al.: Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005, 352:1071–1080.PubMedCrossRefGoogle Scholar
  7. 7.
    Hippisley-Cox J, Coupland C: Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ 2005, 330:1366.PubMedCrossRefGoogle Scholar
  8. 8.
    Farooq M, Haq I, Qureshi AS: Cardiovascular risks of COX inhibition: current perspectives. Expert Opin Pharmacother 2008, 9:1311–1319.PubMedCrossRefGoogle Scholar
  9. 9.
    Warner TD, Mitchell JA: Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. FASEB J 2004, 18:790–804.PubMedCrossRefGoogle Scholar
  10. 10.
    Jenkins C, Costello J, Hodge L: Systematic review of prevalence of aspirin induced asthma and its implications for clinical practice. BMJ 2004, 328:434.PubMedCrossRefGoogle Scholar
  11. 11.
    Rubenstein JH, Laine L: Systematic review: the hepatotoxicity of non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 2004, 20:373–380.PubMedCrossRefGoogle Scholar
  12. 12.
    Patrono C, García Rodríguez LA, Landolfi R, Baigent C: Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 2005, 353:2373–2383.PubMedCrossRefGoogle Scholar
  13. 13.
    Brodie BB, Axelrod J: The fate of acetophenetidin in man and methods for the estimation of acetophenetidin and its metabolites in biological material. J Pharmacol Exp Ther 1949, 97:58–67.PubMedGoogle Scholar
  14. 14.
    Hinz B, Cheremina O, Brune K: Acetaminophen (paracetamol) is a selective cyclooxygenase-2 inhibitor in man. FASEB J 2008, 22:383–390.PubMedCrossRefGoogle Scholar
  15. 15.
    Scanzello CR, Moskowitz NK, Gibofsky A: The post-NSAID era: what to use now for the pharmacologic treatment of pain and inflammation in osteoarthritis. Curr Rheumatol Rep 2008, 10:49–56.PubMedCrossRefGoogle Scholar
  16. 16.
    Botting RM: Mechanism of action of acetaminophen: is there a cyclooxygenase 3? Clin Infect Dis 2000, 31(Suppl 5):S202–S210.PubMedCrossRefGoogle Scholar
  17. 17.
    Kis B, Snipes JA, Busija DW: Acetaminophen and the cyclooxygenase-3 puzzle: sorting out facts, fictions, and uncertainties. J Pharmacol Exp Ther 2005, 315:1–7.PubMedCrossRefGoogle Scholar
  18. 18.
    Rahme E, Barkun A, Nedjar H, et al.: Hospitalizations for upper and lower GI events associated with traditional NSAIDs and acetaminophen among the elderly in Quebec, Canada. Am J Gastroenterol 2008, 103:872–882.PubMedCrossRefGoogle Scholar
  19. 19.
    Niemi TT, Backman JT, Syrjälä MT, et al.: Platelet dysfunction after intravenous ketorolac or propacetamol. Acta Anaesthesiol Scand 2000, 44:69–74.PubMedCrossRefGoogle Scholar
  20. 20.
    Mour G, Feinfeld DA, Caraccio T, McGuigan M: Acute renal dysfunction in acetaminophen poisoning. Ren Fail 2005, 27:381–383.PubMedGoogle Scholar
  21. 21.
    Chan AT, Manson JE, Albert CM, et al.: Nonsteroidal antiinflammatory drugs, acetaminophen, and the risk of cardiovascular events. Circulation 2006, 113:1578–1587.PubMedCrossRefGoogle Scholar
  22. 22.
    Forman JP, Stampfer MJ, Curhan GC: Non-narcotic analgesic dose and risk of incident hypertension in US women. Hypertension 2005, 46:500–507.PubMedCrossRefGoogle Scholar
  23. 23.
    Watkins PB, Kaplowitz N, Slattery JT, et al.: Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily: a randomized controlled trial. JAMA 2006, 296:87–93.PubMedCrossRefGoogle Scholar
  24. 24.
    Björnsson E, Jerlstad P, Bergqvist A, Olsson R: Fulminant drug-induced hepatic failure leading to death or liver transplantation in Sweden. Scand J Gastroenterol 2005, 40:1095–1101.PubMedCrossRefGoogle Scholar
  25. 25.
    Krähenbuhl S, Brauchli Y, Kummer O, et al.: Acute liver failure in two patients with regular alcohol consumption ingesting paracetamol at therapeutic dosage. Digestion 2007, 75:232–237.PubMedCrossRefGoogle Scholar
  26. 26.
    Mahadevan SB, McKiernan PJ, Davies P, Kelly DA: Paracetamol induced hepatotoxicity. Arch Dis Child 2006, 91:598–603.PubMedCrossRefGoogle Scholar
  27. 27.
    Squires RH Jr, Shneider BL, Bucuvalas J, et al.: Acute liver failure in children: the first 348 patients in the pediatric acute liver failure study group. J Pediatr 2006, 148:652–658.PubMedCrossRefGoogle Scholar
  28. 28.
    Lee WM: Acetaminophen toxicity: changing perceptions on a social/medical issue. Hepatology 2007, 46:966–970.PubMedCrossRefGoogle Scholar
  29. 29.
    Bradley JD, Brandt KD, Katz BP, et al.: Comparison of an antiinflammatory dose of ibuprofen, an analgesic dose of ibuprofen, and acetaminophen in the treatment of patients with osteoarthritis of the knee. N Engl J Med 1991, 325:87–91.PubMedGoogle Scholar
  30. 30.
    Pincus T, Koch GG, Sokka T, et al.: A randomized, doubleblind, crossover clinical trial of diclofenac plus misoprostol versus acetaminophen in patients with osteoarthritis of the hip or knee. Arthritis Rheum 2001, 44:1587–1598.PubMedCrossRefGoogle Scholar
  31. 31.
    Case JP, Baliunas AJ, Block JA: Lack of efficacy of acetaminophen in treating symptomatic knee osteoarthritis: a randomized, double-blind, placebo-controlled comparison trial with diclofenac sodium. Arch Intern Med 2003, 163:169–178.PubMedCrossRefGoogle Scholar
  32. 32.
    Pincus T, Koch G, Lei H, et al.: Patient Preference for Placebo, Acetaminophen (paracetamol) or Celecoxib Efficacy Studies (PACES): two randomised, double blind, placebo controlled, crossover clinical trials in patients with knee or hip osteoarthritis. Ann Rheum Dis 2004, 63:931–939.PubMedCrossRefGoogle Scholar
  33. 33.
    Towheed TE, Maxwell L, Judd MG, et al.: Acetaminophen for osteoarthritis. Cochrane Database System Rev 2006, 1:CD004257.Google Scholar
  34. 34.
    Grosser T, Fries S, FitzGerald GA: Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest 2006, 116:4–15.PubMedCrossRefGoogle Scholar
  35. 35.
    Lanas A, Scheiman J: Low-dose aspirin and upper gastrointestinal damage: epidemiology, prevention and treatment. Curr Med Res Opin 2007, 23:163–173.PubMedCrossRefGoogle Scholar
  36. 36.
    Kaufman DW, Kelly JP, Sheehan JE, et al.: Nonsteroidal anti-inflammatory drug use in relation to major upper gastrointestinal bleeding. Clin Pharmacol Ther 1993, 53:485–494.PubMedGoogle Scholar
  37. 37.
    Fosbøl E, Gislason G, Jacobsen S, et al.: Risk of myocardial infarction and death associated with the use of nonsteroidal anti-inflammatory drugs (NSAIDs) among healthy individuals: a nationwide cohort study. Clin Pharmacol Ther 2008 (in press).Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  1. 1.Department of Experimental and Clinical Pharmacology and ToxicologyFAU Erlangen-NurembergErlangenGermany

Personalised recommendations